30.11.2017 • News

Clariant Gets China OK for Stabilizers Site

(c) twitter.com/clariant
(c) twitter.com/clariant

Following the signing of a joint venture with Tiangang Auxiliary in September, Clariant has been given the go-ahead by China’s local authorities to purchase a site for its proposed light stabilizers plant The assignment of the land within the Cangzhou National Coastal-Port Economy and Technology Development Zone in Hebei province was officially confirmed on Nov. 20.

“The demand for high-end additives solutions is growing strongly in China. With the merger control clearance successfully confirmed in October, we are pleased to complete this next important step with our trusted partners towards establishing local production that will accelerate response times, shorten supply lead times and deliver tailored solutions to our customers in the growing Asia region, especially in China,” said Stephan Lynen, head of Clariant’s Additives Business Unit.

Zhang Guo Dong, standing member of the Cangzhou Municipal Party Committee of the Chinese Communist Party, said he hopes the area could explore more opportunities with Clariant based on the existing cooperation so as to introduce more foreign advanced technologies into the area.

The plant, which will initially produce stabilizers for the textile and automotive industries, is scheduled to go on stream in the first half of 2019. Details on capacity and equity stakes in the jv were not revealed.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read